CN110051627A - 包含rpl554的液体吸入制剂 - Google Patents

包含rpl554的液体吸入制剂 Download PDF

Info

Publication number
CN110051627A
CN110051627A CN201811561721.4A CN201811561721A CN110051627A CN 110051627 A CN110051627 A CN 110051627A CN 201811561721 A CN201811561721 A CN 201811561721A CN 110051627 A CN110051627 A CN 110051627A
Authority
CN
China
Prior art keywords
rpl554
liquid pharmaceutical
pharmaceutical composition
composition according
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811561721.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·L·斯帕戈
E·J·弗伦奇
P·A·海伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wei Luona Drugmaker
Original Assignee
Wei Luona Drugmaker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Wei Luona Drugmaker filed Critical Wei Luona Drugmaker
Publication of CN110051627A publication Critical patent/CN110051627A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201811561721.4A 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂 Pending CN110051627A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1416274.7 2014-09-15
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
GB1504662.6 2015-03-19
CN201580053062.1A CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580053062.1A Division CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Publications (1)

Publication Number Publication Date
CN110051627A true CN110051627A (zh) 2019-07-26

Family

ID=54196992

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201811561721.4A Pending CN110051627A (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
CN201580053062.1A Active CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
CN202010090019.5A Active CN111249260B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580053062.1A Active CN106794157B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂
CN202010090019.5A Active CN111249260B (zh) 2014-09-15 2015-09-15 包含rpl554的液体吸入制剂

Country Status (27)

Country Link
US (2) US9956171B2 (enExample)
EP (3) EP3332767B1 (enExample)
JP (2) JP6860477B2 (enExample)
KR (1) KR102379309B1 (enExample)
CN (3) CN110051627A (enExample)
AU (3) AU2015316592B2 (enExample)
CA (1) CA2959943C (enExample)
CY (3) CY1120264T1 (enExample)
DK (3) DK3332767T3 (enExample)
ES (3) ES2730810T3 (enExample)
HK (1) HK1249415B (enExample)
HR (3) HRP20180833T1 (enExample)
HU (3) HUE045303T2 (enExample)
IL (1) IL250895B (enExample)
LT (3) LT3332767T (enExample)
MX (1) MX2017003102A (enExample)
MY (1) MY196072A (enExample)
NO (1) NO3193835T3 (enExample)
PH (1) PH12017500479B1 (enExample)
PL (3) PL3193835T3 (enExample)
PT (3) PT3193835T (enExample)
RS (3) RS58897B1 (enExample)
RU (1) RU2699995C2 (enExample)
SG (1) SG11201701854WA (enExample)
SI (3) SI3332767T1 (enExample)
SM (3) SMT201800242T1 (enExample)
WO (1) WO2016042313A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
CA2959943C (en) * 2014-09-15 2022-08-16 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
CN107849092A (zh) 2015-07-24 2018-03-27 豪夫迈·罗氏有限公司 Bace1抑制剂肽
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
KR20220127845A (ko) * 2020-01-15 2022-09-20 치아타이 티안큉 파마수티컬 그룹 주식회사 삼환 pde3/pde4 이중 억제제 화합물의 약학적 조성물
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
JP2025528141A (ja) * 2022-08-08 2025-08-26 ヴェローナ ファーマ ピーエルシー 液体医薬組成物
EP4568678A1 (en) * 2022-08-08 2025-06-18 Verona Pharma PLC Ensifentrine (rpl-554) for decreasing the frequency and/or severity of copd exacerbations
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
US20250073240A1 (en) * 2023-09-06 2025-03-06 Verona Pharma Plc New treatment
WO2025168546A1 (en) * 2024-02-05 2025-08-14 Verona Pharma Plc Ensifentrine for the treatment of copd
US20250249007A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348453A (zh) * 1999-03-31 2002-05-08 韦尔纳利斯有限公司 嘧啶并[6,1－a] 异喹啉－4－酮衍生物
EP1449528A1 (en) * 2000-04-07 2004-08-25 Arakis Limited Treatment of respiratory diseases
CN1553801A (zh) * 2001-09-12 2004-12-08 含三环5,6-二氢-9H-吡唑并(3,4-C)-1,2,4-三唑并(4,3-α)嘧啶的吸入组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
ATE216244T1 (de) 1997-10-09 2002-05-15 Schering Corp Mometasonfuroat-suspensionen zum zerstäuben
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2011161018A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
BR112013003087A2 (pt) 2010-08-09 2016-07-05 Verona Pharma Plc forma cristalina de composto de pirimidio[6,1-a]-isoquinolin-4-ona
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
CA2902400C (en) * 2013-03-15 2021-05-04 Verona Pharma Plc Pde3/4 inhibitor/.beta.2-adrenergic agonist combination
US10897787B2 (en) * 2014-03-11 2021-01-19 Lg Electronics Inc. Method and apparatus for device-to-device user equipment to transmit discovery signal in wireless communication system
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
CA2959943C (en) * 2014-09-15 2022-08-16 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348453A (zh) * 1999-03-31 2002-05-08 韦尔纳利斯有限公司 嘧啶并[6,1－a] 异喹啉－4－酮衍生物
EP1449528A1 (en) * 2000-04-07 2004-08-25 Arakis Limited Treatment of respiratory diseases
CN1553801A (zh) * 2001-09-12 2004-12-08 含三环5,6-二氢-9H-吡唑并(3,4-C)-1,2,4-三唑并(4,3-α)嘧啶的吸入组合物

Also Published As

Publication number Publication date
PL3193835T3 (pl) 2018-07-31
LT3332767T (lt) 2019-06-25
NZ767295A (en) 2024-01-26
JP2019069978A (ja) 2019-05-09
RU2017108432A3 (enExample) 2019-04-01
SMT201900340T1 (it) 2019-07-11
WO2016042313A1 (en) 2016-03-24
KR102379309B1 (ko) 2022-03-28
AU2020203081A1 (en) 2020-05-28
HRP20191122T1 (hr) 2019-09-20
JP6860477B2 (ja) 2021-04-14
RS62252B1 (sr) 2021-09-30
PT3193835T (pt) 2018-03-27
RU2699995C2 (ru) 2019-09-12
US10945950B2 (en) 2021-03-16
PL3494962T3 (pl) 2021-12-06
AU2015316592A1 (en) 2017-03-23
ES2730810T3 (es) 2019-11-12
SG11201701854WA (en) 2017-04-27
MX2017003102A (es) 2017-06-14
RS58897B1 (sr) 2019-08-30
PH12017500479B1 (en) 2021-07-21
PT3332767T (pt) 2019-06-27
HUE038433T2 (hu) 2018-10-29
MY196072A (en) 2023-03-13
US20180369139A1 (en) 2018-12-27
CN111249260A (zh) 2020-06-09
JP2017528479A (ja) 2017-09-28
RS57227B1 (sr) 2018-07-31
SI3332767T1 (sl) 2019-07-31
HK1249415B (en) 2019-11-22
DK3494962T3 (da) 2021-06-21
EP3494962B1 (en) 2021-05-26
KR20170054406A (ko) 2017-05-17
NZ767296A (en) 2024-01-26
ES2670025T3 (es) 2018-05-29
CY1124546T1 (el) 2022-07-22
HRP20211035T1 (hr) 2021-09-17
SI3494962T1 (sl) 2021-09-30
EP3332767B1 (en) 2019-03-20
PL3332767T3 (pl) 2019-10-31
AU2020203081B2 (en) 2021-08-05
EP3193835A1 (en) 2017-07-26
HRP20180833T1 (hr) 2018-06-29
HUE045303T2 (hu) 2019-12-30
SMT202100479T1 (it) 2021-09-14
IL250895A0 (en) 2017-04-30
US20170239178A1 (en) 2017-08-24
RU2017108432A (ru) 2018-10-17
CY1120264T1 (el) 2019-07-10
CN111249260B (zh) 2023-01-10
JP6795574B2 (ja) 2020-12-02
EP3332767A1 (en) 2018-06-13
EP3193835B1 (en) 2018-03-07
SMT201800242T1 (it) 2018-07-17
PT3494962T (pt) 2021-06-22
AU2018286571B2 (en) 2020-04-02
HUE055527T2 (hu) 2021-12-28
IL250895B (en) 2019-08-29
CY1121698T1 (el) 2020-07-31
DK3193835T3 (en) 2018-05-07
CN106794157B (zh) 2021-03-09
SI3193835T1 (en) 2018-06-29
LT3494962T (lt) 2021-07-26
EP3494962A1 (en) 2019-06-12
DK3332767T3 (da) 2019-06-24
CA2959943A1 (en) 2016-03-24
CA2959943C (en) 2022-08-16
CN106794157A (zh) 2017-05-31
BR112017005050A2 (pt) 2018-01-23
AU2015316592B2 (en) 2020-04-02
ES2875584T3 (es) 2021-11-10
AU2018286571A1 (en) 2019-01-24
LT3193835T (lt) 2018-06-11
NZ729796A (en) 2024-01-26
PH12017500479A1 (en) 2017-07-31
US9956171B2 (en) 2018-05-01
NO3193835T3 (enExample) 2018-08-04

Similar Documents

Publication Publication Date Title
CN106794157B (zh) 包含rpl554的液体吸入制剂
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
EP4110292B1 (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
HK40007474A (en) Liquid inhalation formulation comprising rpl554
HK40007474B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK40097440A (en) Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination